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Background: The prevalence of osteoarthritis (OA) increases with obesity, with up to two thirds of the elderly
obese population affected by OA of the knee. The metabolic syndrome (MetS), frequently associated with central
obesity and characterised by elevated waist circumference, raised fasting plasma glucose concentration, raised
triglycerides, reduced high-density lipoproteins, and/or hypertension, is implicated in the pathogenesis of OA. This
narrative review discusses the mechanisms involved in the influence of MetS on OA, with a focus on the effects on
macrophages and chondrocytes.
Main text: A skewing of macrophages towards a pro-inflammatory M1 phenotype within synovial and adipose
tissues is thought to play a role in OA pathogenesis. The metabolic perturbations typical of MetS are important
drivers of pro-inflammatory macrophage polarisation and activity. This is mediated via alterations in the levels and
activities of the cellular nutrient sensors 5′ adenosine monophosphate-activated protein kinase (AMPK) and
mammalian target of rapamycin complex 1 (mTORC1), intracellular accumulation of metabolic intermediates such
as succinate and citrate, and increases in free fatty acids (FFAs) and hyperglycaemia-induced advanced glycation
end-products (AGEs) that bind to receptors on the macrophage surface. Altered levels of adipokines, including
leptin and adiponectin, further influence macrophage polarisation. The metabolic alterations in MetS also affect the
cartilage through direct effects on chondrocytes by stimulating the production of pro-inflammatory and catabolic
factors and possibly by suppressing autophagy and promoting cellular senescence.
Conclusions: The influence of MetS on OA pathogenesis involves a wide range of metabolic alterations that
directly affect macrophages and chondrocytes. The relative burden of intra-articular versus systemic adipose tissue
in the MetS-associated OA remains to be clarified. Understanding how altered metabolism interacts with joints
affected by OA is crucial for the development of further strategies for treating this debilitating condition, such as
supplementing existing therapies with metformin and utilising ω-3 fatty acid derivatives to restore imbalances in
ω-3 and ω-6 fatty acids.
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Osteoarthritis (OA) is a painful and debilitating degenera-
tive joint disease characterised by progressive loss of ar-
ticular cartilage, synovitis, subchondral bone sclerosis, and
osteophyte formation. An increasing body of evidence in-
dicates that chronic low-level inflammation plays an im-
portant role in the pathogenesis of OA. The presence of
synovitis, characterised by infiltration of immune cells,
angiogenesis, and synovial hypertrophy/hyperplasia, has© The Author(s). 2019 Open Access This artic
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disease progression [1, 2].
The prevalence of OA increases with obesity, with up to
two thirds of the elderly obese population affected by OA
of the knee [3]. The metabolic syndrome (MetS), fre-
quently associated with central obesity, could promote in-
flammatory processes implicated in the pathogenesis of
OA. This narrative review will discuss the influence of
MetS and obesity on OA, with a specific focus on the
mechanisms through which MetS can influence inflam-
matory processes, particularly the activation and polarisa-
tion of macrophages, including perturbations in cellular
nutrient sensing, adipokine production, and long-chainle is distributed under the terms of the Creative Commons Attribution 4.0
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the management of OA and the potential of dietary fatty
acids as targets for future therapies.
Methods
A literature review was conducted through an electronic
search of MEDLINE and PubMed search engines to
identify relevant papers using the following keywords:
osteoarthritis, obesity, metabolic syndrome, hypergly-
caemia, hypertension, infrapatellar fat pad, macrophage,
and chondrocyte. Further electronic searches were con-
ducted for specific proteins of interest that emerged
from the initial searches. Additional references were
identified from reference lists to supplement electronic
searching. Final references for inclusion were selected to
provide substantial coverage of the reviewed topics,
whilst adhering to the editorial guidelines regarding the
number of citations.
Association between MetS and OA
Evidence from epidemiological studies
MetS can be defined as the presence of any three of the
following risk factors: elevated waist circumference,
raised fasting plasma glucose concentration, raised tri-
glycerides, reduced high-density lipoproteins, or hyper-
tension [4]. MetS is accompanied by chronic low-grade
systemic inflammation [5]. The clinical importance of
this has been increasingly recognised, with conditions
driven by chronic inflammation such as psoriasis linked
to MetS [6]. For OA, the strongest epidemiological links
are found between MetS and OA of the knee [7]. A
greater body mass, commonly associated with MetS, and
a resulting increase in the forces acting on the load-
bearing joints may be in part responsible for this associ-
ation. However, obesity also increases the risk of devel-
opment of OA in non-weight-bearing joints of the hand
[7]. Irrespective of a patient’s BMI, hyperlipidaemia and
hypertension as individual MetS components have been
linked to the development of OA [8]. These and other
studies [9] thus provide evidence linking MetS to OA in-
dependent of a patient’s BMI.
Evidence from preclinical studies and the role of
inflammation
The link between MetS and OA is supported by preclin-
ical studies. A commonly used experimental model in ro-
dents is a high-fat diet (HFD), which leads to obesity,
hyperglycaemia and dyslipidaemia, and OA. HFD can also
exacerbate post-traumatic OA in mice [10]. Wheel-
running exercise, and hence increased biomechanical
forces exerted on joints, protected from HFD-induced
OA, and this was associated with improved glucose toler-
ance without reducing body fat [11]. This indicates that
biomechanics alone cannot account for the worsening ofOA, at least in rodents, and that exercise may be joint pro-
tective through improving metabolic function. In addition,
HFD-induced OA is associated with systemic elevations in
pro-inflammatory cytokines [11]. Local adipose tissue
such as the infrapatellar fat pad (IFP) in the knee may also
produce inflammatory and catabolic mediators that con-
tribute to OA pathogenesis and has been implicated as a
source of inflammatory cytokines in both murine HFD-
induced OA [12] and in human rheumatoid arthritis and
OA [13]. Indeed, the IFP from OA patients was shown to
have significantly increased levels of IL-6, monocyte
chemoattractant protein-1 (MCP-1), vascular endothelial
growth factor (VEGF), and leptin, whilst also showing in-
creased levels of fibrosis compared to healthy controls
[14]. Furthermore, when compared to autologous sub-
cutaneous fat, intra-articular adipose tissue within the
infrapatellar and suprapatellar and acetabular fat pads all
showed significantly increased levels of vascularity, fibro-
sis, and inflammatory mediators in OA patient samples
[15]. It must be noted that OA changes within the intra-
articular adipose tissues were unaffected by the presence
of obesity. Similarly, other studies have disputed whether
HFD leads to changes within the IFP, with no evidence
found for an increase in inflammation nor adipocyte
hypertrophy in the IFP in response to HFD, as had been
observed in epididymal fat [16]. This suggests that the IFP
may not undergo similar inflammatory changes in re-
sponse to HFD as abdominal adipose tissue. It is increas-
ingly recognised that differences in cellular composition
and metabolic function exist between adipose depots. This
is potentially a result of adipocyte populations arising from
differing embryological sources [17] and the heteroge-
neous nature of the progenitor cell populations found
within individual depots [18]. Intriguingly, these popula-
tions undergo significant alterations in the presence of
diabetes [18]. Whilst research into the diverse nature of
adipocyte biology is ongoing, our knowledge regarding
intra-articular adipose tissue is particularly limited in rela-
tion to its insulin responsiveness, lipid handling proper-
ties, and response to inflammation. Thus, the relative
importance of local versus systemic adipose inflammation,
and of metabolic dysregulation, in the MetS-associated
OA remains to be clarified.
Macrophages as key effector cells in OA
Infiltrating macrophages are key cells in the inflamma-
tory processes. They are heterogeneous cells that exhibit
remarkable plasticity, able to adopt many phenotypes
and functions dependent on the microenvironmental
signals they receive. Knowledge of the range of macro-
phage activation states and the cues that induce polarisa-
tion is far from complete, but two broad types of
macrophage activation have been characterised: M1-
activated macrophages are induced by pro-inflammatory
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toxic properties that can damage tissue and rely heavily
on glycolysis to meet their energy demands. By contrast,
M2-activated macrophages are anti-inflammatory or rep-
arative and use oxidative phosphorylation to provide a
sustained ATP energy provision. A spectrum of activa-
tion states intermediate to these is found in infiltrating
macrophages in vivo [19].
Early evidence for macrophages playing a key role in
the development of OA came from murine studies utilis-
ing liposomal clodronate to selectively ablate macro-
phages. Osteophyte formation in a model of collagenase-
induced OA was significantly reduced by up to 84%
when macrophages were ablated prior to inducing OA
[20], which was suggested to be due to the reductions in
bone morphogenetic protein (BMP) 2 and 4 production
by synovial lining macrophages [20]. In addition, macro-
phage ablation resulted in reduced levels of MMP2,
MMP3, and MMP9 and decreased cartilage breakdown
[21]. These experiments indicate the importance of mac-
rophages in the disease process.
Activated macrophages have since been shown to be dir-
ectly involved in the development of synovitis in human
OA as visualised by etarfolatide-enhanced single-photon
emission computed tomography-computed tomography
(SPECT-CT) [22]. Etarfolatide binds only to the functional
form of folate receptor β, expressed abundantly on acti-
vated macrophages but not on resting macrophages. OA
patients were shown to have increased numbers of acti-
vated synovial macrophages compared to healthy controls,
and macrophage numbers were significantly associated with
pain and joint space narrowing [22]. It was further shown
that elevated soluble biomarkers, CD14 and CD163, indica-
tive of macrophage activation, in the synovial fluid were sig-
nificantly associated with increased abundance of activated
synovial membrane macrophages when compared to the
etarfolatide scanning results, worsening patient pain scores,
and progression of OA as measured by Kellgren-Lawrence
plain radiograph severity scoring [23]. Thus, these studies
not only indicate that macrophages play an important role
in the underlying disease process but that biomarkers of ac-
tivated macrophages may be able to predict patients at high
risk of disease progression.
It has been proposed that the activation and infiltra-
tion of macrophages into the synovium is brought about
by an initial insult to the joint, releasing damage-
associated molecular patterns (DAMPs) that are recog-
nised by a selection of pattern recognition receptors
(PRRs) expressed on macrophages (Fig. 1). Macrophage
recognition of DAMPs, including high-mobility group
box-1 (HMGB1), S100A8 alarmins, and MMPs, leads to
their activation, transcription of NF-κB, and subsequent
production of pro-inflammatory mediators such as TNF,
interleukin (IL)-1β, and IL-6 [24]. This release of pro-inflammatory mediators leads to the activation of
fibroblast-like synoviocytes and production of MMPs
and disintegrin and metalloproteinases with thrombos-
pondin motifs (ADAMTS), which cause degradation of
the cartilage through cleavage of aggrecan and other car-
tilage matrix proteins [25]. Meanwhile, both activated
macrophages and fibroblasts release chemotactic pro-
teins such as chemokine ligand (CCL) 2, CCL3, and
CCL4 inducing infiltration of circulating monocytes and
CD4+ T cells into the synovium, where the former dif-
ferentiate into macrophages [26]. As well as DAMPs,
metabolic intermediates can polarise macrophages to
different functional states that affect their roles in OA. A
study characterising the phenotype of macrophages iso-
lated from synovial fluid showed that OA patients have a
preponderance to an M1/M2 imbalance with a greater
ratio of M1/M2 correlating with increasing severity of
radiographic OA [27].
The effect of MetS on macrophage polarisation
Macrophages are present in metabolic tissues such as
fat, liver, and muscle, and their proliferation, plasticity,
and polarisation are driven by obesity, with a switch
from the M2 to M1 phenotype being observed [28]. Pre-
clinical studies have demonstrated a skewing of macro-
phages towards the M1 phenotype within synovial and
adipose tissues in diet-induced OA [16]. There are sev-
eral molecular mechanisms through which MetS could
promote a pro-inflammatory M1 macrophage phenotype
in OA, including metabolic perturbations at the cellular
level and changes in the systemic factors such as adipo-
kine levels.
Metabolic programming of macrophage polarisation
Metabolic perturbations, including changes in the levels
of oxygen, nutrients, and extracellular metabolites, are
perceived by immune cells including macrophages
through the activity and levels of the nutrient sensors 5′
adenosine monophosphate-activated protein kinase
(AMPK), and mammalian target of rapamycin complex
1 (mTORC1). The activity of AMPK plays a key role in
metabolic reprogramming in response to nutrient
deprivation (Fig. 2), via its ability to sense falling intra-
cellular glucose and ATP levels. AMPK activity subse-
quently increases ATP production whilst reducing
anabolic processes to restore cellular energy homeostasis
[29]. AMPK activity is reduced by several aspects of
MetS including insulin resistance, hyperglycaemia, and
elevated circulating pro-inflammatory mediators. A re-
duction in AMPK activity in macrophages increases aer-
obic glycolysis by stabilising hypoxia-inducible factor-1α
(HIF-1α) via the Warburg effect. Increased glycolysis in
macrophages is associated with a pro-inflammatory
phenotype as it produces more glucose-6-phosphate
Fig. 1 Chronic inflammation in osteoarthritis. a (Left) healthy synovial joint. Type A and B synoviocytes present within intimal synovial lining. The
cartilage covering the articulating surface of bones. (Right) chronic inflammation within the synovial joint. b Expanded view of chronic inflammation.
DAMPs released from the cartilage and synovium result in synoviocyte activation. Macrophages and CD4+ T cells infiltrate the synovium resulting in
the release of pro-inflammatory mediators and chronic inflammation. The cartilage and bone are degraded and remodelled with subchondral sclerosis
and osteophyte and cyst formation. (A) Fibrous capsule, (B) subintimal synovial lining, (C) intimal synovial lining, (D) type A synoviocyte, (E) type B
synoviocyte, (F) synovial fluid, (G) cartilage, (H) subchondral sclerosis, (I) subchondral cyst, (J) cartilage degradation, (K) DAMP release, (L) osteophyte
formation, (M) synovial hypertrophy, (N) macrophage infiltration, (O) CD4+ T cell infiltration, and (P) pro-inflammatory mediator secretion
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pathway (PPP), allowing the production of NADPH that
is used to generate reactive oxygen species (ROS) [30],
implicated in immune cell activation and in the damage
of chondrocytes. Indeed, G6P-dehydrogenase (G6PD),
the first enzyme within the PPP, has been shown to be
upregulated in macrophages derived from obese patients
and, along with NADPH, to be essential for the activa-
tion of NF-κB and ROS formation [31].
The nutrient sensor mTORC1 integrates signals from
multiple sources, including cellular energy levels, oxygen
status, growth factors, and amino acid availability, and is
responsible for anabolic processes including protein,
lipid, and nucleotide synthesis. Obesity and nutrient ex-
cess are known to induce the hyperactivation of
mTORC1, which leads to defective M2 polarisation of
macrophages via feedback inhibition of the serine-
threonine kinase Akt [32]. Akt is responsible for upregu-
lating many of the genes essential in M2 polarisation
such as Arg1, Fizz1, and Ym1 whilst at the same time
promoting the inhibition of M1 polarisation through
downregulating transcription factor FOXO1, essential
for PRR, Toll-like receptor 4 (TLR4) production andupregulating IL-1 receptor-associated kinase M (IRAK-
M), a TLR4 signalling inhibitor [32]. Similar effects were
observed in a murine OA model. Myeloid lineage-specific
deletion of tuberous sclerosis complex 1 (TSC1) led to hy-
peractivation of mTORC1 and was associated with M1
polarisation of synovial macrophages with resultant in-
creases in IL-1, IL-6, and TNF [33]. This skewing to the
M1 phenotype was accompanied by worsening of OA.
Furthermore, in Rheb1 deletion mice where mTORC1 is
constitutively inactive in the myeloid lineage, it led to M2
macrophage polarisation within the synovium accompan-
ied by improvements in OA histological severity. A recent
study in rheumatoid arthritis further highlights the detri-
mental effects that altered AMPK and mTORC1 activity
can have on synovial inflammation via effects on T cells. T
cells from RA patients were shown to have deficient N-
myristoylation, a lipid modification of proteins that
changes their physical properties and their subcellular dis-
tribution [34]. Defective N-myristoylation of AMPK pre-
vented its activation and instead led to exuberant
mTORC1 signalling, stimulating differentiation into pro-
inflammatory TH1 and TH17 T cells and promoting in-
flammation in a humanised mouse model of synovitis
Fig. 2 Metabolic polarisation of macrophages. Circulating monocytes are recruited into the synovium whereby they differentiate into non-
activated macrophages. Hyperglycaemia, insulin resistance, and pro-inflammatory cytokines inhibit AMPK activity resulting in HIF-1α stabilisation
and increases in aerobic glycolysis. Increases in glycolysis are accompanied by increased PPP activity, and both are involved in M1 macrophage
polarisation. Succinate stabilises HIF-1α. Citrate promotes aerobic glycolysis and inflammatory cytokine expression. Obesity and nutrient excess
hyperactivate mTORC1 resulting in Akt inhibition and defective M2 polarisation. M2 polarisation is promoted by AMPK activity. AMPK is stimulated
by nutrient deprivation, metformin, and adiponectin. Resolvin D1 promotes the re-polarisation of macrophages to the M1 phenotype. AMPK, 5′
adenosine monophosphate-activated protein kinase; HIF-1α, hypoxia-inducible factor alpha; PPP, pentose phosphate pathway; mTORC1, mammalian
target of rapamycin complex 1; TNF-α, tumour necrosis factor alpha; MMP, matrix metalloproteinase; ROS, reactive oxygen species; IL, interleukin; TGF-
β, transforming growth factor beta; VEGF, vascular endothelial growth factor. (A) CD11c, (B) CD14, (C) CD86, and (D) CD206
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OA remains to be determined.
MetS can also impact on crucial metabolites involved
in macrophage polarisation and activity. One of these
metabolic intermediates is succinate. It increases not
only due to the Krebs cycle stalling in M1 macrophages
but also in response to hyperglycaemia and obesity. Suc-
cinate has been shown to compete with prolyl hydroxy-
lase resulting in the stabilisation of HIF-1α within
macrophages with subsequent sustained production ofIL-1β through directly binding to the Il1b promoter
[35]. The stalled Krebs cycle causes the accumulation
of a further intermediate, citrate, within the mito-
chondria that is crucial to M1 effector function. Cit-
rate is exported out of the mitochondria and is
further metabolised to acetyl-CoA, vital in the acetyl-
ation of histones regulating not only the transcription
of glycolytic enzymes, needed to increase energy pro-
duction in the M1 macrophage, but also of inflamma-
tory cytokines such as IL-6 [36].
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In addition to affecting key nutrient sensors and meta-
bolic intermediates that polarise macrophages, the MetS
can influence macrophage function via advanced glyca-
tion end-products (AGEs) and free fatty acids (FFAs)
that act directly on macrophages. Chronic hypergly-
caemia non-enzymatically glycates proteins and lipids
and thus produces advanced glycation end-products
(AGEs). AGEs are recognised by receptors for AGEs
(RAGEs) expressed upon macrophages and their activa-
tion results in M1 polarisation and increased transcrip-
tion of TNF and IL-1β via NF-κB [37]. A similar effect
occurs due to FFAs. Prolonged periods of overnutrition
initially lead to healthy adipose expansion, but when this
capacity becomes exceeded, adipocytes are no longer
able to safely store lipids and protect other tissue from
their deleterious effects as excess lipids remain acellular
in the form of FFAs. FFAs bind to TLR4, resulting in
M1 macrophage activation and pro-inflammatory cyto-
kine production [38].
The influence of adipokines on macrophage polarisation
Leptin, the first adipokine discovered, plays a critical role
in controlling food intake through central mechanisms.
In addition, it is now considered to have an inflamma-
tory role. Leptin activates the JAK2-STAT3 and PI3K-
AKT-mTOR pathways in macrophages to promote a
pro-inflammatory phenotype with the secretion of TNFα
and IL-1β [39]. Leptin concentrations in the synovial
fluid of OA patients correlate with BMI [40]. In addition
to adipose tissue, leptin is produced locally within the
joint by the cartilage, IFP, and synoviocytes [40], and
leptin levels are significantly higher in the synovial fluid
than in the serum of OA patients [41]. Expression in
cartilage is upregulated in OA [40] and correlates with
BMI of the patient [41], suggesting an important role for
locally increased leptin production by joint tissues. In
support of the clinical relevance of leptin in OA develop-
ment, leptin serum levels 10 years prior to MRI assess-
ment were associated with cartilage defects, bone
marrow lesions, osteophytes, meniscal abnormalities,
synovitis, and joint effusion in a population of middle-
aged women [42]. These findings provide a strong indi-
cation for a role of leptin in the pathophysiology of OA.
Adiponectin, another adipokine produced by adipose
tissue, has also been shown to influence macrophage po-
larisation state. Macrophages activated by M2 stimu-
lants, IL-4 and IL-13, were shown to have increased
AMPK activity and fatty acid oxidation when exposed to
adiponectin. This resulted in increased levels of IL-10—a
hallmark of M2 macrophage effector function. However,
adiponectin also appeared to promote TNF, IL-6, and
IL-12 production when macrophages were exposed to
M1 polarising conditions [43]. In contrast, in a series ofin vitro experiments, adiponectin was shown to promote
re-polarisation of M1 macrophages towards an M2
phenotype, indicating a possible role in the resolution of
inflammation [44]. Accordingly, a longitudinal study re-
ported that OA progressed more slowly in patients with
higher levels of adiponectin within their synovial fluid.
Interestingly, adiponectin levels were inversely propor-
tional to patients BMI [45]. This inverse relationship be-
tween adiponectin levels and BMI may be explained by
adiponectin production being sensitive to both oxidative
stress and fibrosis occurring in unhealthy adipose tissue
expansion associated with obesity [46]. Thus, obesity
and MetS downregulate one of the adipokines that may
confer protection against OA via its effects on the innate
immune system. However, another study showed that
plasma adiponectin levels and adiponectin production by
OA cartilage positively correlated with OA severity in a
cohort of 35 patients undergoing total knee replacement
surgery [47]. The role of adiponectin in OA pathophysi-
ology thus remains to be clarified.
The effect of MetS on chondrocytes
The metabolic perturbations associated with MetS, in
addition to influencing macrophage polarisation and ac-
tivity as outlined above, can contribute to OA pathogen-
esis by directly affecting chondrocytes. Both decreased
AMPK and hyperactivation of mTORC1 resulting from
MetS can negatively affect chondrocytes. A recent study
in cartilage-specific AMPK knockout mice demonstrated
increased degradation of cartilage in both age-related
OA and post-traumatic OA due, at least in part, to the
loss of protection from the catabolic effects of IL-1β ac-
tivating NF-ϰB and resulting in the production of MMPs
[48]. This has been corroborated by the selective AMPK
activator, A769669, shown to significantly reduce cartil-
age breakdown in human chondrocytes exposed to IL-1β
and TNF [49]. mTORC1 hyperactivation has been impli-
cated in the development of OA through its suppression
of autophagy. Autophagy, as a mechanism for recycling
damaged cellular organelles, is vital for cell survival.
Rapamycin blockade of mTORC1 activity has been
shown to significantly increase autophagy within articu-
lar chondrocytes and reduce OA severity, accompanied
by reductions in both synovitis and ADAMTS-5 expres-
sion in the articular cartilage [50]. Elevated levels of
FFAs may also directly affect chondrocytes within the
OA joint. When human chondrocytes are cultured in
the presence of saturated FFAs, it results in the in-
creased expression of the inflammatory cytokines IL-6
and IL-8. Concurrently, superoxide radical, reactive ni-
trogen species, and hydrogen peroxide were all upregu-
lated within the human chondrocytes [51]. Furthermore,
leptin has been shown to affect chondrocytes via its abil-
ity to stimulate chondrocytes to produce numerous
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analysis of cartilage from rats with leptin-induced OA
and healthy controls revealed increased expression of
genes encoding for MMPs, inflammatory cytokines, and
apoptotic factors in the leptin-induced OA group [52].
Similarly, human chondrocytes stimulated with leptin
upregulate MMP1, MMP3, and MMP-13 [53], and in-
crease nitric oxide synthase type II when leptin is com-
bined with IL-1β [54]. Finally, leptin has been reported
to induce cell senescence in chondrocyte progenitors by
activating the p53/p21 pathway and inhibiting Sirt1 (re-
sponsible for degrading p53), resulting in impaired abil-
ity to migrate and differentiate into chondrocytes [55].
Cell senescence is increased in OA cartilage, and senes-
cence is emerging as an important player in OA patho-
genesis. It occurs as a result of cell cycle arrest in
response to cellular stressors, leading to cellular hyper-
trophy and resistance to cell death signals. Importantly,
cell senescence contributes to chronic inflammation
through promoting the senescence-associated secretory
phenotype (SASP). Chondrocytes exhibiting SASP pro-
duce IL-1, IL-6, CCL2, and MMPs amongst other fac-
tors, leading not only to cartilage breakdown and
synovitis but, in a paracrine manner, inducing further
chondrocyte senescence [56]. The importance of these
processes was demonstrated when senescent cell clear-
ance, either through genetic ablation or treatment with
the senolytic agent UBX0101, attenuated the develop-
ment of OA in mice following ACL transection or with
age [57]. Beneficial effects of UBX0101 treatment were
also observed in human OA chondrocytes in vitro [57],
and this agent is currently in a phase I clinical trial for
knee OA (www.clinicaltrials.gov). Taken together, these
data highlight the role of MetS on OA not only via the
activation and polarisation of macrophages but also via
direct detrimental effects on chondrocytes.
Implications for OA treatment
As the body of evidence has built up implicating MetS
in shaping our inflammatory response in the context of
OA, an important question is whether weight loss and
an associated reversal of MetS could lead to the halting
of OA disease progression. Numerous studies have been
conducted assessing the impact of weight loss on meta-
bolic dysfunction with implications for macrophage acti-
vation and systemic inflammation. Diet-induced weight
loss over a 3-month period significantly reduced circu-
lating saturated FFA levels [58]. Weight loss has also
been shown to significantly reduce circulating AGEs,
demonstrated by reductions in HbA1c (glycated haemo-
globin) [59]. As these are known to activate TLR4 and
RAGEs, respectively, weight loss may decrease the acti-
vation and polarisation of M1 macrophages and hence
reduce inflammation. In support of this, OA patientsexperiencing weight loss following bariatric surgery had
significantly reduced serum leptin, IL-6, and high-
sensitivity C-reactive protein levels, and increased serum
adiponectin levels [60]. This was associated with de-
creased pain and improved function scores, as well as in-
creased levels of N-terminal propeptide of type IIA
collagen, indicative of cartilage production, and de-
creased levels of cartilage oligomeric matrix protein, in-
dicative of cartilage degradation [60]. Weight loss can
thus decrease systemic inflammation and alleviate symp-
toms of knee OA.
In addition to weight loss, there has been interest in
drugs such as metformin, used in the treatment of dia-
betes for many years. Metformin primarily acts to reduce
hepatic gluconeogenesis whilst also increasing glucose
utilisation by the intestine, thus reduce AGE formation
implicated in the activation and polarisation of M1 mac-
rophages [61]. Furthermore, its molecular mechanism of
action involves activating AMPK [61], which may have
further protective roles in the context of OA, as dis-
cussed above. Metformin has recently been used in a
prospective cohort study and was shown to reduce car-
tilage loss in OA patients over a 4-year period [62].
Whilst it did fail to reach significance for the reduction
in total knee replacement after 6 years, this may be due
to the relatively small number of participants in the
study who were currently taking metformin and thus re-
mains a promising avenue for future research to deter-
mine the influence metformin may have on OA
progression. It must also be acknowledged, however,
that there are drawbacks to metformin use. Significant
proportions of patients started upon the drug are unable
to tolerate the side effects that often accompany its initi-
ation, most notably gastrointestinal upset [63].
Whilst old drugs such as metformin could potentially
be repurposed for treating OA, there is a need for fur-
ther strategies to combat OA. One such strategy is utilis-
ing dietary ω-3 PUFA derivatives to influence
macrophage polarisation and OA disease progression.
Mice fed different ratios of ω-6 polyunsaturated fatty
acids (PUFAs) compared to ω-3 PUFAs to induce obes-
ity showed significant differences in the severity of OA,
synovitis, and wound healing. Those with greater levels
of ω-6 PUFAs had significantly worse outcomes, as well
as increased leptin and decreased adiponectin levels [64].
However, this is controversial with others demonstrating
mice fed with a ω-6-rich diet over a 24-week period to
have no increased risk of synovitis when compared to
those fed with ω-3 PUFAs [65]. Despite these differing
results, PUFA derivatives have been trialled therapeutic-
ally. The ω-3 PUFA derivative resolvin D1 (RvD1) has
been reported to re-polarise macrophages to an M2
phenotype with decreased production of IL-8, IL-1β, and
CCL2 [66]. Mice receiving a HFD and treated intra-
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post-traumatic OA compared to mice injected with ve-
hicle [67]. This provides insight that RvD1-like mole-
cules could mediate re-polarisation of macrophages and
reduction in inflammation. Results from a 2016 clinical
trial showed oral ω-3 to be beneficial in reducing patient
pain scores in OA but failed to demonstrate any benefit
in reducing cartilage loss [68]. Further investigation is
therefore warranted to determine whether, with a poten-
tial intra-articular route of administration, OA progres-
sion could be slowed, thus paving the way to a potential
DMOAD.
Conclusions
Our understanding of the pathogenesis of OA has come
a long way from the long-standing paradigm of a disease
caused by ‘wear and tear’. A plethora of new evidence
has emerged highlighting the importance of chronic,
low-grade inflammation in the pathogenesis of this de-
bilitating condition. Macrophages, as crucial mediators
of the innate and adaptive immune response, have been
extensively studied, and it is now clear that an imbalance
in macrophage phenotype is contributing to this condi-
tion. Given the association of OA with obesity in an in-
creasingly overweight population, the impact of
metabolic factors on the development of joint disease
has become an area of intense investigation. As such,
dyslipidaemia, hyperglycaemia, and aberrant adipokine
secretion have emerged as important metabolic regula-
tors capable of influencing the chronic inflammation
seen in OA. These discoveries reaffirm the role weight
loss plays in the management of OA, how weight loss
could per se result in resolving inflammation, metformin
can alter metabolic regulators, and how dietary fatty
acids might be promising targets for DMOADs. Whilst
new therapies will require substantial further work to
reach fruition, the studies reviewed here offer significant
encouragement that novel treatments will emerge for
this prevalent and debilitating condition.
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